Oral recombinant human lactoferrin induces systemic immune responses and inhibits the growth of established tumors

B. O'Malley,G. Forni,C. Curcio,K. Petrak,J. Wolf,M. Spadaro,A. Varadhachary,F. Pericle

2004-04-01

Abstract:Proc Amer Assoc Cancer Res, Volume 45, 2004 4689 We investigated the immunomodulatory function and anti-cancer activity of orally administered recombinant human lactoferrin (rhLF), alone and in combination with chemotherapy in tumor-bearing mice. Oral rhLF (300 mg/kg/day for three days) administered to naive Balb/C mice resulted in statistically significant changes with respect to placebo including: (i) increased production of IL-18 in the intestinal tract (8.4 vs. 1.0 ng/ml); (ii) systemic NK activation (34.0 vs. 9.9 lytic units); and (iii) CD8+ T cell expansion in peripheral blood (26% relative increase). IL-18 is known to induce the production of Th1 cytokines including INF-γ, and to enhance cell-mediated immune cytotoxicity via NK and CD8+ T cell activation. We then investigated rhLF’s ability to inhibit tumor growth in syngeneic mice. Monotherapy with oral rhLF (1,000 mg/kg) induced partial or complete regression in mammary adenocarcinoma (TUBO) tumors. Oral rhLF (200 mg/kg) also caused tumor growth inhibition (TGI) in a head and neck squamous cell carcinoma (SCC VII) model: monotherapy with oral rhLF caused a 61% TGI relative to placebo (p<0.001), comparable to Cis-platinum (5 mg/kg) alone (66%). Animals receiving both rhLF (200 mg/kg) and Cis-platinum (5 mg/kg) had a 79% TGI, a statistically significant improvement over either agent alone. These findings suggest that oral rhLF is active against cancer as a single agent and in combination with chemotherapy, and exerts its systemic effect through stimulation of cytokines such as IL-18 from the gut enterocytes. RhLF has been shown to be safe in human clinical trials. Thus, rhLF shows promise as a safe and well-tolerated novel immunomodulatory anticancer agent.

Medicine